Search results for " lung"

showing 10 items of 680 documents

Focal airtrapping at expiratory high-resolution CT: comparison with pulmonary function tests

2000

This study was undertaken to determine prevalence, extent, and severity of focal airtrapping at expiratory high-resolution CT, and to compare focal airtrapping with age, gender, pulmonary function tests, and blood gas analysis. Two-hundred seventeen patients with and without pulmonary disease underwent paired inspiratory/expiratory high-resolution CT. Six scan pairs with corresponding scan levels were visually assessed for focal – not diffuse – airtrapping using a four-point scale. Pulmonary function tests and blood gas analysis were available for correlation in all patients (mean interval 5 days). Focal airtrapping with lower lung predominance was observed in 80 % of patients. Twenty-six o…

AdultLung DiseasesMalemedicine.medical_specialtyAdolescentHigh resolutionSeverity of Illness IndexPulmonary function testingHumansMedicineRadiology Nuclear Medicine and imagingLung volumesProspective StudiesAgedNeuroradiologyAged 80 and overLungbusiness.industryRespirationUltrasoundGeneral MedicineNormal lung functionMiddle AgedRespiratory Function TestsLung densitymedicine.anatomical_structureFemaleRadiologyBlood Gas AnalysisArtifactsTomography X-Ray ComputedbusinessEuropean Radiology
researchProduct

HRCT and scleroderma: semiquantitative evaluation of lung damage and functional abnormalities.

2007

This study sought to validate the Warrick score in the assessment of lung involvement in systemic sclerosis (SSc) and correlate the results with functional abnormalities. In addition, we propose the use of high resolution computed tomography (HRCT) indices of alveolitis and fibrosis to discriminate between different stages of the disease.Thirty-one patients with SSc (16 with the diffuse form and 15 with the limited form) underwent functional and HRCT evaluations of the lung. The semiquantitative evaluation of radiological involvement, as proposed by Warrick, provides a score for each lesion based on the severity and the extent of the pulmonary damage. In addition to the total score, indices…

AdultLung DiseasesMalemedicine.medical_specialtyHigh-resolution computed tomographyGastroenterologySensitivity and SpecificitySeverity of Illness IndexLesionFibrosisDLCOScleroderma LimitedInternal medicineForced Expiratory VolumePulmonary fibrosisSeverity of illnessmedicineHumansRadiology Nuclear Medicine and imagingLung volumesAgedLungScleroderma Systemicmedicine.diagnostic_testbusiness.industryTotal Lung CapacityGeneral Medicinerespiratory systemMiddle Agedmedicine.diseaseFibrosisrespiratory tract diseasesRespiratory Function TestsPulmonary Alveolimedicine.anatomical_structureScleroderma DiffuseFemalemedicine.symptomlung scleroderma HRCTNuclear medicinebusinessTomography X-Ray ComputedLa Radiologia medica
researchProduct

B-Lines for the assessment of extravascular lung water: Just focused or semi-quantitative?

2020

BACKGROUND B-lines as typical artefacts of lung ultrasound are considered as surrogate measurement for extravascular lung water. However, B-lines develop in the sub-pleural space and do not allow assessment of the whole lung. Here, we present data from the first observational multi-centre study focusing on the correlation between a B-lines score and extravascular lung water in critically ill patients suffering from a variety of diseases. PATIENTS AND METHODS In 184 adult patients, 443 measurements were obtained. B-lines were counted and expressed in a score which was compared to extravascular lung water, measured by single-indicator transpulmonary thermodilution. Appropriate correlation coe…

AdultLung DiseasesMalemedicine.medical_specialtyOxygenation indexCritical IllnessThermodilutionSensitivity and Specificity03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicineProspective StudiesLungAgedUltrasonographyAged 80 and overLungReceiver operating characteristicCritically illbusiness.industry030208 emergency & critical care medicineGeneral MedicineOxygenationMiddle Agedrespiratory tract diseasesLung ultrasoundAnesthesiology and Pain MedicineLung watermedicine.anatomical_structureExtravascular Lung WaterCardiologyFemalebusinessSemi quantitativeActa anaesthesiologica ScandinavicaREFERENCES
researchProduct

Imaging of the lungs using 3he MRI: Preliminary clinical experience in 18 patients with and without lung disease

1997

The purpose of this study was to describe the 3He MRI findings of normal pulmonary ventilation in healthy volunteers and to evaluate abnormalities in patients with different lung diseases. Hyperpolarized 3He gas (300 ml, 3 x 10(5) Pa, polarized to 35-45% by optical pumping, provided in special glass cells) was inhaled by 8 healthy volunteers and 10 patients with different lung diseases. Imaging was performed with a three-dimensional fast low-angle shot (FLASH) sequence (TR = 11.8 msec; TE = 5 msec; transmitter amplitude, 5-8 V; corresponding flip angle, < 5 degrees) in a single breath-hold (22-42 seconds). Clinical and radiological examinations were available for correlation. The studies we…

AdultLung DiseasesMalemedicine.medical_specialtyPleural effusionHyperpolarized Helium 3HeliumSensitivity and SpecificityDiagnosis DifferentialFlip angleHumansMedicineRadiology Nuclear Medicine and imagingLung Diseases ObstructiveLungAgedLungBronchiectasismedicine.diagnostic_testbusiness.industryMagnetic resonance imagingMiddle AgedImage Enhancementmedicine.diseaseMagnetic Resonance ImagingObstructive lung diseaseRespiratory Function TestsHypoventilationmedicine.anatomical_structureFemaleRadiologymedicine.symptomPulmonary VentilationTomography X-Ray ComputedbusinessJournal of Magnetic Resonance Imaging
researchProduct

Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: A phase II trial

2005

A number of second line treatments have been proposed in patients with advanced pretreated non-small cell lung cancer (NSCLC). However, either single agents or two or three drug combinations achieved very poor results with no superiority of any combination over monotherapy. We have treated 42 patients (30 males) affected by advanced/metastatic NSCLC progressing during front line cisplatin-based chemotherapy with a combination of topotecan (1.2 mg/m2) plus ifosfamide (1200 mg/m2) for 3 consecutive days every 3 weeks. The median age was 63 years (range 43-76); cell types were: squamous carcinoma (n=17), adenocarcinoma (n=16), large cell carcinoma (n=3), broncho-alveolar carcinoma (n=2) and un…

AdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniamedicine.medical_treatmentGastroenterologychemistry.chemical_compoundCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIfosfamideInfusions IntravenousLung cancerSurvival rateAgedPlatinumChemotherapyIfosfamidebusiness.industryAlopeciaAnemiaGeneral MedicineMiddle Agedmedicine.diseaseThrombocytopeniaCarboplatinSquamous carcinomaSurgeryOxaliplatinTreatment OutcomeOncologychemistryDrug Resistance NeoplasmFemaleTopotecanTopotecanbusinessmedicine.drug
researchProduct

Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Smal…

2015

Purpose Concurrent chemoradiotherapy with or without surgery are options for stage IIIA(N2) non–small-cell lung cancer. Our previous phase II study had shown the efficacy of induction chemotherapy followed by chemoradiotherapy and surgery in patients with IIIA(N2) disease and with selected IIIB disease. Here, we compared surgery with definitive chemoradiotherapy in resectable stage III disease after induction. Patients and Methods Patients with pathologically proven IIIA(N2) and selected patients with IIIB disease that had medical/functional operability received induction chemotherapy, which consisted of three cycles of cisplatin 50 mg/m2 on days 1 and 8 and paclitaxel 175 mg/m2 on day 1 ev…

AdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsPaclitaxelmedicine.medical_treatmentMedizinPhases of clinical researchVinblastineVinorelbineDrug Administration SchedulePneumonectomyCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPneumonectomyLung cancerAgedNeoplasm Stagingbusiness.industryDose fractionationInduction chemotherapyVinorelbineChemoradiotherapyInduction ChemotherapyMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryRadiation therapyTreatment OutcomeOncologyFemaleDose Fractionation RadiationCisplatinbusinessChemoradiotherapymedicine.drugJournal of Clinical Oncology
researchProduct

Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV …

1997

A multicentric, prospective phase III study was carried out with the aim of testing the so-called 'worst drug rule' hypothesis, which suggests the use of an effective but 'less active' regimen that first eradicates tumoral cells resistant to a second effective and 'more active' regimen. With respect to this hypothesis, we considered the cisplatin plus vinorelbine regimen (CCDP/VNR) as the more active regimen compared with the non-cisplatin-containing regimen of ifosfamide plus high-dose epirubicin (IFO/EPI). Thus, a randomized study was carried out to compare the sequencial strategy of three cycles of CDDP/VNR followed by three cycles of IFO/EPI with the opposite sequence in advanced non-sm…

AdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsUrologyVinblastineVinorelbineDrug Administration ScheduleCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIfosfamideProspective StudiesNeoplasm MetastasisLung cancerProspective cohort studyAgedEpirubicinNeoplasm StagingMesnaIfosfamidePerformance statusbusiness.industryVinorelbineMiddle Agedmedicine.diseaseSurgeryRegimenOncologyDisease ProgressionFemaleCisplatinbusinessResearch Articlemedicine.drugEpirubicinBritish Journal of Cancer
researchProduct

Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology P…

2014

Purpose The prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non–small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population. Methods Analysis of ALK status was performed by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) in tissue sections of 1,281 patients with adenocarcinoma in the European Thoracic Oncology Platform Lungscape iBiobank. Positive patients were matched with negative patients in a 1:2 ratio, both for IHC and for …

AdultMaleCancer Researchmedicine.medical_specialtyPathologyLung NeoplasmsPopulation610 Medicine & healthAdenocarcinoma of LungAdenocarcinomaGastroenterologyCohort Studies10049 Institute of Pathology and Molecular Pathologyhemic and lymphatic diseasesThoracic OncologyInternal medicinePrevalencemedicineHumansAnaplastic lymphoma kinase1306 Cancer ResearchAnaplastic Lymphoma KinaseLung cancereducationIn Situ Hybridization FluorescenceAgedNeoplasm Stagingeducation.field_of_studyLungbusiness.industryALK-PositiveReceptor Protein-Tyrosine KinasesMiddle Agedmedicine.diseaseImmunohistochemistryEuropeTreatment Outcomemedicine.anatomical_structureOncology10032 Clinic for Oncology and HematologyImmunohistochemistryAdenocarcinoma2730 OncologyFemalebusiness
researchProduct

Identifying associations between diabetes and acute respiratory distress syndrome in patients with acute hypoxemic respiratory failure: an analysis o…

2018

Background: Diabetes mellitus is a common co-existing disease in the critically ill. Diabetes mellitus may reduce the risk of acute respiratory distress syndrome (ARDS), but data from previous studies are conflicting. The objective of this study was to evaluate associations between pre-existing diabetes mellitus and ARDS in critically ill patients with acute hypoxemic respiratory failure (AHRF). Methods: An ancillary analysis of a global, multi-centre prospective observational study (LUNG SAFE) was undertaken. LUNG SAFE evaluated all patients admitted to an intensive care unit (ICU) over a 4-week period, that required mechanical ventilation and met AHRF criteria. Patients who had their AHRF…

AdultMaleDiabetes mellituLUNG SAFEOrgan Dysfunction Scoreshumanoslnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]Socio-culturaleOrgan Dysfunction ScoreDiabetes ComplicationsDiabetes mellituspuntuaciones de disfunción orgánicaRisk FactorsDiabetes Complicationestudios prospectivosHumansfactores de riesgoProspective StudiesHospital MortalityHypoxiamediana edadAcute hypoxemic respiratory failureAgedRespiratory Distress SyndromeancianoAcute respiratory distress syndromeResearchRespirationrespiraciónRespiratory Distress Syndrome Adultlcsh:Medical emergencies. Critical care. Intensive care. First aidlcsh:RC86-88.9Middle AgedRespiration Artificialinsuficiencia respiratoriaAcute hypoxemic respiratory failure; Acute respiratory distress syndrome; Diabetes mellitus; LUNG SAFEProspective StudieArtificialAcute hypoxemic respiratory failure; Acute respiratory distress syndrome; Diabetes mellitus; LUNG SAFE; Aged; Diabetes Complications; Diabetes Mellitus; Female; Hospital Mortality; Humans; Hypoxia; Male; Middle Aged; Organ Dysfunction Scores; Prospective Studies; Respiration Artificial; Respiratory Distress Syndrome Adult; Respiratory Insufficiency; Risk FactorsFemaleRespiratory Insufficiencymortalidad hospitalariacomplicaciones de la diabetesHuman
researchProduct

Weekly Dose-Dense Cisplatin-Epirubicin-Paclitaxel Administration with Granulocyte Colony-Stimulating Factor Support Does Not Substantially Improve Pr…

2004

Purpose: The present study was aimed at defining the antitumor activity of the cisplatin-epirubicin-paclitaxel (PET) weekly administration with granulocyte colony-stimulating factor (G-CSF) support in chemonaive small-cell lung cancer patients with extensive disease (ED-SCLC). Methods: Chemonaive ED-SCLC patients received cisplatin 30 mg/sqm, epirubicin 50 mg/sqm and paclitaxel 120 mg/sqm, weekly, with G-CSF (5 μg/kg from day 3 to 5) support, for a maximum of 12 weeks. Results: Thirty-nine patients were treated, for a total of 354 cycles delivered. Eight complete (21%), and 22 partial responses (56%) were recorded, giving a 77% (95% Cl = 61-89%) objective response rate (ORR). After 14 (rang…

AdultMaleLung NeoplasmsPaclitaxelMiddle AgedPrognosisSmall-cell lung cancer Weekly chemotherapy Paclitaxel Epirubicin CisplatinSurvival AnalysisDrug Administration ScheduleTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorHumansFemaleCarcinoma Small CellCisplatinInfusions IntravenousAgedEpirubicin
researchProduct